semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Clostridium Difficile Infection Adult patients, aged ≥ 20 years at the time of hospitalization in specified wards PCR-diagnosed CDI while at the hospital Informed consent has been obtained from patients as required by local requirements  Age < 20 years
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diarrhoea, Clostridium Difficile C. difficile-associated diarrhea at the time of enrollment years old and up Ability to take oral medications Negative urine pregnancy test for women of childbearing age Must have the ability to understand and the willingness to provide a written informed consent to participate in the study  History of known allergy to silicates Patients with signs of toxic megacolon, peritonitis, pseudomembranous colitis or bowel perforation Patients with hypotension (systolic blood pressure < 90 mm Hg) or septic shock requiring pressors Patients with other known causes of diarrhea or colitis Pregnancy or lactation History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up Participation in any other study where the subject is actively taking investigational medication within the last 30 days More than 5 doses of metronidazole or oral vancomycin prior to starting on study drug for the current C. difficile diagnosis. Administration of metronidazole or oral vancomycin for treatment of prior C. difficile diagnosis is not exclusionary as some patients may be experiencing a relapse of C. difficile Any other antibiotic, toxin-binding agent or fecal transplant used for the treatment of C. difficile prior to or added to the subject's standard-of-care treatment regimen. Use of intravenous vancomycin is not exclusionary
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Subarachnoid Hemorrhage (SAH) Tachycardia Age >=18 years Diagnosis of subarachnoid hemorrhage established by computed tomography (CT scan) or xanthochromia of the cerebrospinal fluid if the CT is negative Written informed consent from either the patient or a family member Admitted to the NICU for at least 12 hours  Age < 18yrs traumatic SAH SAH due to a rupture of an arteriovenous malformation, neoplasm vasculitis or other secondary causes
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.5-18.0,  Clostridium Difficile-associated Diarrhea Male or female 6 months to 17 years 11 months of age, inclusive Female subjects of childbearing potential must use adequate contraception Diagnosed with CDAD  Concurrent use of oral vancomycin or metronidazole or any other effective treatments for CDAD Fulminant colitis History of inflammatory bowel disease Pregnant or breast-feeding Need for concurrent use of some P-glycoprotein inhibitors during therapy
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 60.0-90.0,  Hypotension Tachycardia Patients with degenerative joint disease of the knee scheduled to receive unilateral total knee arthroplasty  bilateral total knee arthroplasty, previous knee surgery, cardiac arrhythmia, uncontrolled hypertension (systolic blood pressure > 170 mmHg), presence of a known aortic aneurysm, recent stroke or myocardial infarction, unstable angina pectoris, New York Heart Association functional class III or IV, and American Society of Anesthesiologists physical status IV to V
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Antibiotic-associated Diarrhoea Males and females aged 18-65 years. 2. Patients will be initiating antibiotic therapy. 3. The antibiotic therapy consists of one of the following: broad spectrum penicillins, cephalosporins, doxycycline, clarithromycin, ciprofloxacin or isoxazolyl penicillin. 4. The antibiotic therapy is expected to be 3 to 14 days in duration. 5. Obtained his/her informed consent after verbal and written information. 6. Have a high probability for compliance with and completion of the study. 7. Patients having a telephone available. 8. Body Mass Index between 19 and 30  Participation in a clinical trial with an investigational product or drug within the 60 days prior to screening. 2. Likeliness to be noncompliant with the protocol, or to be unsuitable to the study by the investigator for any reason. 3. Pregnant or breastfeeding women; women planning to become pregnant during the study months. 4. Presence of active diarrhea (3 or more loose or watery stools per 24 hour period). 5. Daily consumption of probiotics, fermented milk and/or yogurt with probiotics. 6. Known to have a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. on-medicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetable source), ascorbic acid, Colloidal silicon dioxide). 7. Presence of an active, non-controlled intestinal disease such as Crohn's Disease or ulcerative colitis. 8. Regular use of proton pump inhibitors. 9. Bowel surgery, artificial heart valve, history of rheumatic heart disease or infective endocarditis. 10. A previous documented C. difficile infection < 3 months prior to study initiation. 11. Immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, AIDS). 12. Ongoing or recent use of antibiotic therapy in the 3 months prior to the study product first administration. 13. Planned administration of antibiotics other than broad spectrum penicillins, cephalosporins, doxycycline, ciprofloxacin or isoxazolyl penicillin for the treatment of an infection. 14. History of drug or alcohol abuse
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Clostridium Difficile Infection To be included in this study, participants must Sign a consent form Be >= 18 and < 90 years of age Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device Test positive for Clostridium difficile If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study. Participants will not be allowed into the study if they Have toxic megacolon and/or known small bowel ileus Have received treatment with intravenous immune globulin (IVIG) within the past 30 days Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Clostridium Difficile Infection Is able to read and sign a consent form Is from ≥18 to <90 years of age Has diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device Tests positive for Clostridium difficile If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study  Has toxic megacolon and/or known small bowel ileus Has received treatment with intravenous immune globulin (IVIG) within the past 30 days Has received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study Has received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working Has received an investigational vaccine against Clostridium difficile Has received an investigational product containing monoclonal antibodies against toxin A or B within 180 days Has more than 2 episodes of CDAD within 90 days Has had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not appendectomy or cholecystectomy) Has a history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis Is unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Osteoarthritis Patients with osteoarthritis scheduled for TKA at the department of orthopedic surgery, Hässleholm Hospital, Sweden, are eligible for participation in the study  body mass index (BMI) > 35 m/kg2 prior major knee surgery to the ipsilateral knee ongoing infection, known immunological deficiency or ASA physical status category > IV
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Watery Diarrhea Dysentery/Febrile Diarrhea Active duty military or military beneficiary, 18 years-old or older. 2. Presence of acute diarrhea (3 or more stools in 24 hours or 2 or more stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) and <96 hours duration. 3. Eligible for ambulatory management. 4. Able to comply with follow-up procedures. 5. Will remain in country for at least 7 days  Allergy to rifamycins, quinolones, macrolides, or loperamide (not including mild gastrointestinal upset). 2. Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, or doxycycline). 3. Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, and warfarin). 4. History of seizures (relative contraindication to quinolones) 5. Positive pregnancy test at presentation (contraindicated with fluoroquinolone therapy). All female subjects will be administered a urine pregnancy test prior to enrollment. 6. Presence of symptoms >96 hours prior to initiating treatment. 7. Use of >4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infection After Primary Total Knee Arthroplasty Primary total knee replacement. Both genders. No age limits  Allergy to erythromycin or colistin. Previous infection in the knee
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 75.0-999.0,  Fever Infection >= 75 years given informed consent  patients who do not speak the German language patients with unstable cardiorespiratory status presence of contraindications to one of the temperature measurement methods
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bleeding Peptic Ulcer Active Bleeding Gastrointestinal Bleeding Overt signs of upper gastrointestinal bleeding (i.e., melena or hematemesis with or without hypotension) 2. GBS of ≥12 3. In-patients admitted for reasons other than AUGIB who develop bleeding are also considered for trial enrollment. 4. Patients in Hypotensive shock (SBP ≤90 mmHg or pulse ≥110 bpm) are initially resuscitated and then considered for trial entry if their condition can be stabilized  continued shock despite initial volume resuscitation (refractory shock) undergo urgent endoscopy 2. < 18 years of age 3. Unable to provide written informed consent 4. Pregnant or lactating women 5. Moribund patients from terminal illnesses. (active treatment not considered)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Adult of either gender, 18 years or older with a first episode of C. difficile infection Meets the case definition of C. difficile infection-diarrhea associated with a positive stool test for C. difficile toxin(s) in the 2 days prior to enrollment treated with metronidazole or vancomycin  Severe disease defined as any of the following: WBC > 30,000 or < 1000 cells/mm^3, elevated creatinine > 1.5 times the premorbid level, ICU patient at time C. difficile infection diagnosed Has other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal disease) Has a history of chronic intestinal disease (e.g. Crohn's disease, ulcerative colitis) Has a presence of toxic megacolon or ileus Has a presence of colostomy or nasogastric tube Has a history of abdominal surgery within the previous 3 months (from time of enrollment) Is enrolled in another investigational drug trial Is unavailable for follow-up visits History of multiple C. difficile infection Willing not to take other probiotics for duration of study
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile-Associated Diarrhea (CDAD) Male or female 18 years of age or older Females of childbearing potential must be using an adequate and reliable method of contraception (e.g., abstinence, barrier with additional spermicide foam or jelly, intrauterine device, hormonal contraception). Males and females must agree to avoid conception during treatment and for four weeks following the end of study treatment Is undergoing HSCT with planned Fluoroquinolone prophylaxis Informed consent is provided  Ongoing active CDAD infection (as evidenced by clinical signs of diarrhea along with the presence of either toxin A and/or B [or their respective genes, tcdA and/or tcdB] of C. difficile in the stool) or current treatment for CDAD Undergoing cord blood transplants Has fulminant colitis, toxic megacolon, or ileus A history of inflammatory bowel disease (ulcerative colitis or Crohn's disease) Women who are pregnant or are actively breast feeding (all women of childbearing potential must have a negative pregnancy test result prior to dosing study drug) Use of any drugs potentially useful in the treatment of CDAD (e.g. oral Vancomycin, Metronidazole, oral Bacitracin, Fusidic Acid, Rifaximin, and Nitazoxanide) Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the participant in the study, would make it unlikely for the participant to complete the study, or would confound the results of the study Participation in other clinical research studies utilizing an investigational agent within one month prior to screening and during the study treatment period
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Clostridium Difficile Adult outpatients (age ≥18 and <75) referred to one of the study centers after suffering a third (or further) documented episode CDI and 2. who have failed to maintain CDI cure after standard therapy with oral vancomycin Previous treatment with at least one course of tapered/pulse dose vancomycin as per SHEA-IDSA C difficile treatment guidelines or -Inability to taper or stop vancomycin without developing diarrhea requiring anti-infective therapy. -  Patients who are aged 75 years or greater Patients who are pregnant Patients who are nursing Patients who are incarcerated Patients with cognitive impairment or severe neuropsychiatric co morbidities who are incapable of giving their own informed consent Patients who are immunocompromised specifically HIV infection (any CD4 count) AIDS-defining diagnosis or CD4<200/mm3 Inherited/primary immune disorders Immunodeficient or Immunosuppressed due to medical condition/medication